

ASX Announcement and Media Release

17 February, 2005

SciGen Limited

Insulin registered in Philippines

The Directors of SciGen Limited (“SciGen” or the “Company”) are pleased to announce that the Company has received health care registration for its insulin product SciLin™ in the Philippines.

According to World Health Organisation statistics, over 2 million Filipinos are diagnosed as having diabetes, with a large number of the population remaining undiagnosed. The Philippines ranks 10th in the list of countries with the highest incidence of diabetes in the world. Industry sources value the total insulin market to be approximately \$US 7million.

Preparations are well underway for the sales launch of SciLin™ in the Philippines to occur as soon as possible.

SciLin™ is a second generation recombinant human insulin that SciGen has the exclusive rights to market in the Asia Pacific Region.

Mark Compton said “We are delighted with yet another regulatory approval for SciLin™. This provides SciGen with not only an expanded market for the product, but also a real opportunity to assist in treating the dramatically escalating problem of diabetes amongst Filipinos.”

SciLin™ is currently registered and sold by SciGen or its partners in India, Vietnam and Pakistan.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland, Switzerland, Austria and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO: Telephone: +61 2 9234 1700: Web: www.scigen.com.au